lisdexamfetamine dimesylate (LDX) - flexible-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - flexible-dose study	efficacy in adolescents with ADHD	4365	4470	LDX was superior to OROS-MPH in adolescents with ADHD in the forced-dose but not the flexible-dose study.
lisdexamfetamine dimesylate (LDX) - forced-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - forced-dose study	Improvement on the dichotomized CGI-I at EOS	28171	28320	Improvement on the dichotomized CGI-I at EOS was significantly greater with lisdexamfetamine than with OROS-MPH in the forced-dose study (p = 0.0188)
lisdexamfetamine dimesylate (LDX) - forced-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - forced-dose study	change from baseline on the ADHD-RS-IV hyperactivity/impulsivity and inattentiveness subscales	2681	2969	change from baseline on the ADHD-RS-IV hyperactivity/impulsivity and inattentiveness subscales nominally favored LDX in the forced-dose study (hyperactivity/impulsivity subscale −1.3 ± 0.49, nominal p = 0.0081, ES −0.27; inattentiveness subscale −2.0 ± 0.63, nominal p = 0.0013, ES −0.33)
lisdexamfetamine dimesylate (LDX) - flexible-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - flexible-dose study	efficacy in adolescents with ADHD	2637	3066	The LS mean ± SEM treatment differences for change from baseline on the ADHD-RS-IV hyperactivity/impulsivity and inattentiveness subscales nominally favored LDX in the forced-dose study (hyperactivity/impulsivity subscale −1.3 ± 0.49, nominal p = 0.0081, ES −0.27; inattentiveness subscale −2.0 ± 0.63, nominal p = 0.0013, ES −0.33), but there were no significant differences between active treatments in the flexible-dose study.
lisdexamfetamine dimesylate (LDX) - forced-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - forced-dose study	efficacy in adolescents with ADHD	4365	4469	LDX was superior to OROS-MPH in adolescents with ADHD in the forced-dose but not the flexible-dose study
lisdexamfetamine dimesylate (LDX) - flexible-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - flexible-dose study	efficacy in adolescents with ADHD	2370	2636	The percentage of improved participants on the dichotomized CGI-I at end of treatment was significantly greater with LDX than with OROS-MPH in the forced-dose study (81.4 vs. 71.3%, p = 0.0188) but not the flexible-dose study (LDX 83.1%, OROS-MPH 81.0%, p = 0.6165).
lisdexamfetamine dimesylate (LDX) - flexible-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - flexible-dose study	efficacy in adolescents with ADHD	4365	4469	LDX was superior to OROS-MPH in adolescents with ADHD in the forced-dose but not the flexible-dose study
lisdexamfetamine dimesylate (LDX) - flexible-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - flexible-dose study	efficacy in adolescents with ADHD	2128	2369	LS mean ± SEM treatment difference for the change from baseline significantly favored LDX over OROS-MPH in the forced-dose [−3.4 ± 1.04, p = 0.0013, effect size (ES) −0.33] but not the flexible-dose (−2.1 ± 1.15, p = 0.0717, ES −0.20) study.
lisdexamfetamine dimesylate (LDX) - forced-dose study	osmotic-release oral system methylphenidate (OROS-MPH) - forced-dose study	Improvement on the dichotomized CGI-I at EOS	2370	2636	The percentage of improved participants on the dichotomized CGI-I at end of treatment was significantly greater with LDX than with OROS-MPH in the forced-dose study (81.4 vs. 71.3%, p = 0.0188) but not the flexible-dose study (LDX 83.1%, OROS-MPH 81.0%, p = 0.6165).
